ABBOTT LABORATORIES - Common Stock (ABT)

Historical Holders from Q1 2014 to Q4 2025

Symbol: ABT on NYSE
Type / Class: Equity / Common Stock
Shares outstanding: 1,740,239,592
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 1,353,057,249
Holdings value: $181,143,451,313
% of all portfolios: 0.14%
Number of holders: 3,128
Number of buys: 1,311
Number of sells: 1,443
Average buys %: +0.01%
Average sells %: -0.01%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of ABBOTT LABORATORIES - Common Stock (ABT) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	10%		$22,211,548,033		174,894,079		The Vanguard Group	28 Nov 2025

As of 30 Sep 2025 ABBOTT LABORATORIES - Common Stock (ABT) has 3,128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,353,057,249 shares of 1,740,239,592 outstanding shares and own 78% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of ABBOTT LABORATORIES - Common Stock (ABT) own 49% of the company based on 13F filings as of 30 Sep 2025

Filer	Ownership	Holdings Value	Nb Shares	Share Change %
VANGUARD GROUP INC	10%	$23,192,288,014	173,154,308	+0.2%
BlackRock, Inc.	8.1%	$18,960,540,594	141,559,956	+0.19%
STATE STREET CORP	4.5%	$10,477,589,235	78,225,991	-0.16%
Capital International Investors	3.5%	$8,251,973,846	61,614,739	+2.5%
Capital Research Global Investors	2.2%	$5,192,680,251	38,768,839	-7.2%
MORGAN STANLEY	2.2%	$5,174,745,037	38,634,796	+9.7%
GEODE CAPITAL MANAGEMENT, LLC	2.2%	$5,138,229,944	38,541,894	+0.65%
JPMORGAN CHASE & CO	1.7%	$3,935,602,588	29,383,217	-25%
WELLINGTON MANAGEMENT GROUP LLP	1.3%	$3,113,588,527	23,246,144	-7.2%
BANK OF AMERICA CORP /DE/	1.2%	$2,786,732,240	20,805,826	-4.1%
NORTHERN TRUST CORP	1.2%	$2,738,111,311	20,442,820	-2.8%
T. Rowe Price Investment Management, Inc.	1%	$2,379,993,000	17,769,095	+112%
WELLS FARGO & COMPANY/MN	0.96%	$2,237,781,227	16,707,340	-2.8%
GOLDMAN SACHS GROUP INC	0.93%	$2,160,212,460	16,128,211	+6.1%
PRICE T ROWE ASSOCIATES INC /MD/	0.91%	$2,116,355,000	15,800,759	+53%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	0.87%	$2,022,079,724	15,096,907	+5.8%
Invesco Ltd.	0.8%	$1,868,718,439	13,951,907	+51%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	0.78%	$1,819,858,585	13,587,118	0%
AMERIPRISE FINANCIAL INC	0.78%	$1,804,050,308	13,500,829	+3.8%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.75%	$1,759,615,804	13,137,337	-0.3%
Legal & General Group Plc	0.74%	$1,727,868,591	12,900,318	+7.2%
Bank of New York Mellon Corp	0.73%	$1,698,160,020	12,678,513	-0.47%
Fisher Asset Management, LLC	0.69%	$1,611,684,674	12,032,884	+1.4%
Nuveen, LLC	0.67%	$1,561,011,931	11,654,561	-4.6%
FMR LLC	0.67%	$1,552,712,104	11,592,594	-15%

Institutional Holders of ABBOTT LABORATORIES - Common Stock (ABT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	1,151,130	$148,773,227	-$2,106,727			$125.29	40
2025 Q3	1,353,057,249	$181,143,451,313	-$2,756,916,176	$1,094,806,792	$1,324,182,319	$133.94	3,128
2025 Q2	1,373,457,328	$186,724,601,473	+$3,689,370,235	$984,050,549	$1,190,798,948	$136.01	3,151
2025 Q1	1,348,790,206	$178,801,336,976	+$458,110,755	$1,066,676,118	$1,230,814,569	$132.65	3,135
2024 Q4	1,346,298,072	$152,329,939,683	+$4,602,128,635	$892,314,424	$1,137,484,789	$113.11	3,033
2024 Q3	1,300,355,763	$148,247,878,720	-$1,716,781,783	$912,604,110	$990,236,464	$114.01	2,874
2024 Q2	1,316,417,932	$136,784,452,486	+$2,136,359,246	$737,676,751	$891,749,395	$103.91	2,843
2024 Q1	1,302,852,431	$147,952,633,332	-$186,373,857	$983,430,929	$955,728,962	$113.66	2,884
2023 Q4	1,304,983,629	$143,636,729,289	+$702,840,266	$959,849,696	$1,195,846,672	$110.07	2,868
2023 Q3	1,296,567,862	$125,616,929,945	-$511,707,264	$655,596,868	$884,812,579	$96.85	2,664
2023 Q2	1,300,801,326	$141,636,058,128	-$238,716,500	$705,091,045	$846,508,711	$109.02	2,714
2023 Q1	1,303,370,319	$131,997,378,367	+$456,259,624	$700,544,402	$762,510,181	$101.26	2,685
2022 Q4	1,295,641,185	$142,311,403,748	-$88,117,082	$906,174,803	$1,123,449,745	$109.79	2,741
2022 Q3	1,295,186,205	$125,419,250,679	+$340,947,519	$763,132,868	$869,978,416	$96.76	2,596
2022 Q2	1,292,982,597	$140,507,109,818	+$1,291,772,556	$470,095,211	$669,456,180	$108.65	2,676
2022 Q1	1,290,037,320	$152,773,075,671	-$1,347,741,981	$732,919,156	$881,067,208	$118.36	2,744
2021 Q4	1,298,568,047	$182,637,730,877	-$1,037,752,022	$1,318,526,242	$1,285,267,786	$140.74	2,792
2021 Q3	1,304,329,872	$154,105,545,758	-$489,063,797	$996,921,283	$894,214,519	$118.13	2,518
2021 Q2	1,308,302,318	$151,667,725,087	-$1,382,462,665	$891,234,450	$768,886,884	$115.93	2,492
2021 Q1	1,318,091,663	$157,927,510,389	+$1,631,328,365	$747,326,040	$766,688,704	$119.84	2,510
2020 Q4	1,307,462,033	$143,116,956,354	+$331,022,292	$717,522,875	$785,419,000	$109.49	2,473
2020 Q3	1,306,014,624	$142,022,460,179	-$6,984,888	$836,428,452	$799,217,646	$108.83	2,293
2020 Q2	1,304,304,663	$119,298,426,006	-$1,426,498,089	$554,493,000	$539,586,000	$91.43	2,237
2020 Q1	1,320,881,349	$104,282,756,007	-$474,548,989	$431,584,000	$505,931,000	$78.91	2,118
2019 Q4	1,324,729,656	$115,053,827,077	+$582,610,959	$620,512,000	$643,769,000	$86.86	2,181
2019 Q3	1,320,917,464	$110,486,349,698	-$172,855,428	$510,277,000	$540,768,000	$83.67	2,020
2019 Q2	1,320,235,491	$111,014,490,159	+$1,880,435,078	$348,142,000	$575,297,000	$84.10	2,003
2019 Q1	1,313,334,925	$104,961,645,831	-$610,840,495	$305,280,000	$523,248,000	$79.94	1,992
2018 Q4	1,321,863,765	$95,580,892,549	+$1,894,141,670	$350,534,000	$653,955,000	$72.33	1,962
2018 Q3	1,293,120,470	$94,835,420,854	+$2,995,171,785	$452,873,000	$665,921,000	$73.36	1,856
2018 Q2	1,254,589,153	$76,508,542,840	-$964,494,217	$173,973,000	$269,275,000	$60.99	1,801
2018 Q1	1,274,488,709	$76,351,995,921	+$368,748,979	$192,811,064	$265,087,656	$59.92	1,796
2017 Q4	1,267,615,293	$72,341,691,509	-$422,486,325	$249,035,893	$270,341,591	$57.07	1,746
2017 Q3	1,273,140,330	$67,943,393,768	+$614,368,368	$245,772,000	$334,319,000	$53.36	1,591
2017 Q2	1,263,195,777	$61,401,759,006	+$808,713,177	$267,275,000	$290,360,000	$48.61	1,569
2017 Q1	1,251,255,326	$55,565,381,743	+$10,527,320,695	$227,752,949	$255,608,000	$44.41	1,585
2016 Q4	1,106,373,205	$42,516,265,016	+$407,904,281	$268,142,000	$238,723,000	$38.41	1,514
2016 Q3	1,091,633,492	$46,138,705,256	+$1,153,981,971	$258,463,000	$449,585,000	$42.29	1,484
2016 Q2	1,067,624,130	$41,983,022,819	+$1,701,516,839	$186,027,000	$203,588,000	$39.31	1,467
2016 Q1	1,022,822,267	$42,778,202,179	-$173,321,678	$122,647,000	$144,261,000	$41.83	1,457
2015 Q4	1,027,740,304	$46,154,356,293	-$497,206,316	$229,118,000	$242,306,000	$44.91	1,498
2015 Q3	1,037,112,499	$41,717,834,562	+$274,539,953	$212,793,000	$291,387,000	$40.22	1,452
2015 Q2	1,033,961,965	$50,752,165,358	+$294,425,750	$639,114,000	$480,241,000	$49.08	1,478
2015 Q1	1,028,648,801	$47,650,459,140	-$625,423,849	$169,836,000	$218,054,000	$46.33	1,463
2014 Q4	1,043,914,792	$46,996,777,711	+$448,236,438	$240,485,000	$257,914,000	$45.02	1,472
2014 Q3	1,028,753,494	$42,786,861,710	+$362,567,670	$179,718,000	$194,608,000	$41.59	1,388
2014 Q2	1,019,994,541	$41,715,229,215	+$96,928,621	$127,902,000	$284,359,000	$40.90	1,377
2014 Q1	1,020,830,174	$39,305,027,565	-$1,235,422,500	$137,087,000	$156,312,000	$38.51	1,367